FIELD: chemistry; medicine.
SUBSTANCE: invention refers to medical products, and related to the use of therapeutically safe and effective amount of combination of nebivolol or its pharmaceutical salt and ramiprilat or elanapril or their pharmaceutical salt to get a medical product that improves NO release in black patient and results in decreased mortality related to cardiovascular diseases.
EFFECT: proposed combination has synergy effect on endothelium dependent NO release from the cells of black donors.
4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS CONTAINING NEBIVOLOL | 2010 |
|
RU2593335C2 |
| GLUCURONIDATED NEBIVOLOL METABOLITES | 2006 |
|
RU2413518C2 |
| PHARMACEUTIC COMPOSITION, WHICH CONTAINS HYDROXYLATED NEBIVOLOL | 2006 |
|
RU2433823C2 |
| PHARMACEUTICAL COMPOSITION ELICITING IMPROVED ANTITUMOR EFFECT AND/OR REDUCED ADVERSE EFFECTS AND COMPRISING ANTITUMOR AGENT AND DERIVATIVE OF HYDROXAMIC ACID | 1998 |
|
RU2254129C2 |
| CONDENSED HETEROCYCLIC SUCCINAMIDE COMPOUNDS | 2001 |
|
RU2298554C2 |
| METHOD OF PRODUCING DERIVATIVES OF DELTA 4-9-19-NORSTEROIDS | 0 |
|
SU1340593A3 |
| 19,11-BRIDGED OVER 4-ESTRENES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION, INTERMEDIATE COMPOUNDS | 1993 |
|
RU2157814C2 |
| METHOD FOR THE SYNTHESIS OF STEROID, SUBSTITUTED WITH SPIRANE CYCLE | 0 |
|
SU1715205A3 |
| TLR7 AGONISTS | 2019 |
|
RU2817014C2 |
| AGONISTS OF 5-HT4-RECEPTORS FOR TREATING DEMENTIA | 2011 |
|
RU2569733C2 |
